ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

FCRF Contracts Recompetition Will Be Along Same Lines As in 1982 But for at Least Seven Years

July 5, 1985

LeMaistre Blasts “Death Merchants’ In tobacco Industry

May 5, 1989

Professional Fundraiser Poses Eight Questions For SU2C 3.

September 19, 2008

NCCN, McKesson Form Partnership To Build Clinical Support Software

November 30, 2012

In Brief: Hammer Reappointed chairman; Wyngaarden Names Ferguson of Baylor As OMAR Director

July 29, 1988

Chart of Core Grants

October 18, 1991